<html xml:lang="en-us" lang="en-us" xmlns="http://www.w3.org/1999/xhtml" xmlns:epub="http://www.idpf.org/2007/ops"><head>
    <link rel="stylesheet" type="text/css" href="../../../../css/base.css" />
<link rel="stylesheet" type="text/css" href="../../../../css/kotobeeInteractive.css" />
<link rel="stylesheet" type="text/css" href="../../../../css/global.css" />
<link rel="stylesheet" type="text/css" href="../css/base.css" />
<link rel="stylesheet" type="text/css" href="../css/global.css" />
<link rel="stylesheet" type="text/css" href="../css/kotobeeInteractive.css" />

    <script type="text/javascript" src="../../../../js/kotobeeInteractive.js"></script>
<script type="text/javascript" src="../../../../js/global.js"></script>
<script type="text/javascript" src="../js/kotobeeInteractive.js"></script>
<script type="text/javascript" src="../js/global.js"></script>

    <title>Methadone for refractory pain</title>
    

<meta name="m-checksum" content="-787779733" />
<meta charset="utf-8" />
 <meta name="kotobee-chapter" content="epubypzqs\EPUB\xhtml\s530xo.xhtml" />
<meta name="kotobee-book" content="urn:uuid:6760033b-6528-f338-e97c-0ff6e727c70d" />
</head>
<body>
<p><strong><em>Methadone in palliative patients should only be used under the direction of a palliative care specialist. Speak to one before initiating methadone.</em></strong></p>

<p>Methadone often provides good analgesia in patients with terminal illnesses.</p>

<p>It has unusual pharmacokinetics with a very long half-life of days and toxicity can occur unexpectedly after a week or more of an apparently well tolerated dose regimen.</p>

<p><strong>Indication: </strong>Pain refractory to other treatment, especially pain associated with a neuropathic component, opioid-tolerance or central sensitisation</p>

<p><strong>Some advantages of methadone</strong></p>

<ul>
	<li>Dosing unaffected by renal failure</li>
	<li>Often brings significant benefits at low doses allowing for major reduction in the dose of other opioids. It may also be beneficial in opioid-induced hyperalgesia</li>
</ul>

<p><strong>Commencing methadone</strong></p>

<ul>
	<li>Guidelines for using methadone in the palliative context vary widely. This guideline suggests a conservative approach where low-dose methadone is added on top the patient’s current analgesia</li>
	<li>Before starting exclude a prolonged QTc by performing an ECG</li>
	<li>Start at 5mg orally at night. Continue any pre-existing regular and PRN analgesia</li>
</ul>

<p><strong>Increasing the dose</strong></p>

<ul>
	<li>If inadequate analgesia is achieved within 3-5 days, the dose can be increased to 5mg twice daily. Monitor for adverse effects</li>
	<li>The dose can be increased further in small 5mg increments ever 5-7 days if necessary, however speak to a senior palliative care doctor</li>
	<li>Recheck the ECG after 2-4 weeks to ensure that the QTc interval remains &lt; 0.5</li>
	<li>Consider gradually reducing the dose of other background opioids such as a fentanyl patch whilst titrating up the methadone, especially if adverse effects or a poor response to these opioids (or opioid-induced hyperalgesia) is suspected.</li>
</ul>

<p><strong>Long-term dosing and stopping methadone</strong></p>

<ul>
	<li>If significant side effects occur (e.g. sedation and reduced respiratory rate) then stop the methadone and reduce other opioids. In serious cases naloxone may be needed</li>
	<li>If there is no apparent improvement with methadone cease it</li>
	<li>If there is good analgesia, consider reducing the dose of other long-acting opioids and continuing the methadone longer term</li>
</ul>

<table>
	<tbody>
		<tr>
			<td><strong>Precautions</strong></td>
		</tr>
		<tr>
			<td>Previous arrhythmias</td>
		</tr>
		<tr>
			<td>Prolonged QTc &gt; 0.5</td>
		</tr>
		<tr>
			<td>Any reason to be cautious with any opioid</td>
		</tr>
	</tbody>
</table>

<p>&#160;</p>

<table>
	<tbody>
		<tr>
			<td><strong>Adverse Effects</strong></td>
		</tr>
		<tr>
			<td>Sedation</td>
		</tr>
		<tr>
			<td>Respiratory depression</td>
		</tr>
		<tr>
			<td>Arrhythmias associated with QT prolongation</td>
		</tr>
		<tr>
			<td>Constipation</td>
		</tr>
		<tr>
			<td>Nausea</td>
		</tr>
	</tbody>
</table>

<p>&#160;</p>

<p><strong>Subcutaneous use:</strong></p>

<ul>
	<li>10mg oral ≈ 10mg subcut</li>
	<li>Give as twice daily subcut boluses or a CSCI</li>
	<li>Compatibilities:
	<ul>
		<li><a class="link523" href="../../../raw/scboqn.xhtml">Methadone (without another opioid) comptabilities</a></li>
		<li><a class="link856" href="../../../raw/s28n1u.xhtml">Methadone (with another opioid) compatibilities</a></li>
	</ul>
	</li>
</ul>

<p>&#160;</p>


</body></html>